GT Medical lands $10m Series A for IsoRay ’ s GammaTile

GT Medical Technologies said today that it landed a $10 million Series A round for the GammaTile brachytherapy it co-developed with IsoRay (NYSE:ISR) to treat brain tumors. Richland, Wash.-based IsoRay and the Barrow Neurological Institute formed GT Medical to develop the technology to embed Cesium-131 brachytherapy seeds in collagen tiles to treat malignant meningioma, according to regulatory filings, inking a formal co-development deal in March 2017. By January of the following year the deal had expanded to include an exclusive, 10-year manufacturing &supply pact for GammaTile. In July 2018 GammaTile won 510(k) clearance from the FDA. Today GT Medical said proceeds from the Series A round, led by MedTech Venture Partners with participation from BlueStone Venture Partners, are earmarked for further GammaTile commercialization. The device is already under limited release. “GammaTile Therapy was developed by a team of brain tumor specialists who were running out of options for their patients. Their urgency to find a viable solution for these patients led to the creation of GammaTile Therapy, which is designed to be immediate, safe, predictable, and effective,” GT Medical president &CEO Matthew Likens said in prepared remarks. “With this funding, in addition to adding seasoned industry executives to our team, we look forward to building and expanding our commercialization efforts so that we can offer this new option to pat...
Source: Mass Device - Category: Medical Devices Authors: Tags: Featured Funding Roundup Radiosurgery/Radiation therapy Wall Street Beat GT Medical Technologies IsoRay Source Type: news

Related Links:

ConclusionThese data establish that [89Zr]anti-CD11b Ab immunoPET targets CD11b+ cells (TAMCs) with high specificity in a mouse model of GBM, demonstrating the potential for non-invasive quantification of tumor-infiltrating CD11b+ immune cells during disease progression and immunotherapy in patients with GBM.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
Abstract A poly(amidoamine) dendrimer (PAMAM, G5) based drug delivery system was developed for the treatment of glioma. PAMAM was modified with polyethylene glycol (PEG) to improve its in vivo stability and reduce immunogenicity. Further, the internalized RGD (iRGD) recognition ligand of the integrin αvβ3 receptor and the blood-brain barrier (BBB)-targeting group TGN were introduced. Arsenic trioxide (ATO) was loaded into the internal cavity through electrostatic interactions to form iRGD/TGN-PEG-PAMAM-ATO. The drug delivery system of iRGD/TGN dual-modified PAMAM, which entrapped ATO, had a high en...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
In this study, we collected and evaluated the epigenetically regulated-mRNA expression-based stemness index (EREG-mRNAsi) of The Cancer Genome Atlas (TCGA,http://www.ncbi.nlm.nih.gov/) for glioma patient samples, corrected through tumor purity. After EREG-mRNAsi correction, glioma pathological grade and survival were analyzed. The differentially expressed gene (DEG) co-expression network was constructed by weighted gene co-expression network analysis (WGCNA) in TCGA glioma samples to find modules of interest and key genes. Gene ontology (GO) and pathway-enrichment analysis were performed to identify the function of signifi...
Source: Journal of Molecular Neuroscience - Category: Neuroscience Source Type: research
Cancers, Vol. 12, Pages 1354: Incidence, Therapy, and Bleeding Risk—Cancer- Associated Thrombosis in Patients with Glioblastoma Cancers doi: 10.3390/cancers12061354 Authors: Viktoria Muster Thomas Gary Cancer is an independent risk factor for the development of venous thromboembolism (VTE). Glioblastomas are amongst cancer types with the most thrombogenic potential and patients are at a particularly high risk of VTE with an incidence up to 20–30% per year. Currently, major efforts are underway to gain novel insights into risk factors and pathomechanisms to provide a better understanding of develop...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Condition:   Central Nervous System Diseases Interventions:   Drug: Dexmedetomidine;   Drug: Normal saline Sponsor:   Capital Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: The experiment results indicate that the proposed model yields a promising performance in automated brain tumor segmentation. PMID: 32444591 [PubMed - as supplied by publisher]
Source: Journal of X-Ray Science and Technology - Category: Radiology Tags: J Xray Sci Technol Source Type: research
Condition:   Central Nervous System Diseases Interventions:   Drug: Dexmedetomidine;   Drug: Normal saline Sponsor:   Capital Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Improved efficacy of anti-cancer therapy and a growing pool of survivors give rise to a question about their quality of life and return to premorbid status. Radiation is effective in brain metastasis eradication, though the optimal approach and long-term effects on brain function are largely unknown. Here, we studied the effects of radiosurgery on brain function.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
AbstractHere, we report on a 28-year old male patient presenting with neck and shoulder pain, dysesthesia of all four limbs and hypesthesia of both hands, without motor deficits. Magnetic resonance imaging showed an intradural, intramedullary mass of the cervical spinal cord of 6.4  cm length and 1.7 cm diameter. The patient underwent surgical resection. Histological and immunohistochemical evaluation showed pleomorphic glial tumor cells, mitoses, calcifications, and atypical ganglioid cells compatible with the morphology of anaplastic ganglioglioma (WHO Grade III). Extensiv e molecular workup revealedH3F3A K27M,...
Source: Brain Tumor Pathology - Category: Neurology Source Type: research
ConclusionsHigh uptake of68Ga-PSMA and18F-DCFPyL in the peritumoral area of all glioma models is presumably caused by activated astrocytes. This may represent a limitation for the clinical application of PSMA ligands in gliomas.
Source: EJNMMI Research - Category: Radiology Source Type: research
More News: Brachytherapy | Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Funding | Men | Neurology | Radiation Therapy | USA Health